• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

普瑞巴林口服吸收模型的比较:转运室模型的实用性

Comparison of oral absorption models for pregabalin: usefulness of transit compartment model.

作者信息

Hong Taegon, Han Seunghoon, Lee Jongtae, Jeon Sangil, Yim Dong-Seok

机构信息

Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine.

Department of Clinical Pharmacology and Therapeutics, Seoul St Mary's Hospital; PIPET (Pharmacometrics Institute for Practical Education and Training), College of Medicine, The Catholic University of Korea.

出版信息

Drug Des Devel Ther. 2016 Dec 7;10:3995-4003. doi: 10.2147/DDDT.S123318. eCollection 2016.

DOI:10.2147/DDDT.S123318
PMID:27994441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5153293/
Abstract

Pregabalin is an anticonvulsant used for the treatment of neuropathic pain and partial seizure in adults. The aim of this study was to develop a population pharmacokinetic (PK) model to describe the absorption characteristics of pregabalin given fasted or after meals. Data from five healthy subject PK studies (n=88) of single- or multiple-dose pregabalin (150 mg) were used. Pregabalin was administered twice daily, without meals or 30 min after a meal (regular or high-fat diet) in the morning and 30 min or 4 h after a meal (regular diet) in the evening. Serial plasma samples were collected up to 24 h after the last dose for PK analysis. Because the peak concentrations were not properly modeled by a conventional first-order absorption model, Erlang frequency distribution, Weibull-type absorption, and transit compartment models were tested on a two-compartment linear PK model using a nonlinear mixed-effects method (NONMEM; version 7.3). The transit compartment model best described the absorption characteristics of pregabalin regardless of meal status. We conclude that the absorption model should be carefully chosen based on the principle of model development and validation and not by following a conventional first-order absorption model for its popularity and simplicity, especially when the PK dataset includes densely sampled absorption-phase data.

摘要

普瑞巴林是一种抗惊厥药物,用于治疗成人神经性疼痛和部分性癫痫发作。本研究的目的是建立一个群体药代动力学(PK)模型,以描述普瑞巴林在空腹或餐后的吸收特征。使用了五项健康受试者单剂量或多剂量(150毫克)普瑞巴林PK研究(n = 88)的数据。普瑞巴林每日给药两次,早晨不进餐或餐后30分钟(常规饮食或高脂饮食)给药,晚上餐后30分钟或4小时(常规饮食)给药。在最后一剂后长达24小时收集系列血浆样本进行PK分析。由于传统的一级吸收模型无法正确模拟峰浓度,因此使用非线性混合效应方法(NONMEM;版本7.3)在二室线性PK模型上测试了埃尔朗频率分布、韦布尔型吸收和转运室模型。无论进餐状态如何,转运室模型最能描述普瑞巴林的吸收特征。我们得出结论,应根据模型开发和验证的原则仔细选择吸收模型,而不是因其流行和简单而遵循传统的一级吸收模型,尤其是当PK数据集包含密集采样的吸收相数据时。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9b/5153293/df79b09a8e51/dddt-10-3995Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9b/5153293/d33b22294967/dddt-10-3995Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9b/5153293/95c6a65b5252/dddt-10-3995Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9b/5153293/affcfa9a3572/dddt-10-3995Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9b/5153293/df79b09a8e51/dddt-10-3995Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9b/5153293/d33b22294967/dddt-10-3995Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9b/5153293/95c6a65b5252/dddt-10-3995Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9b/5153293/affcfa9a3572/dddt-10-3995Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9b/5153293/df79b09a8e51/dddt-10-3995Fig4.jpg

相似文献

1
Comparison of oral absorption models for pregabalin: usefulness of transit compartment model.普瑞巴林口服吸收模型的比较:转运室模型的实用性
Drug Des Devel Ther. 2016 Dec 7;10:3995-4003. doi: 10.2147/DDDT.S123318. eCollection 2016.
2
Effect of the gastrointestinal prokinetic agent erythromycin on the pharmacokinetics of pregabalin controlled-release in healthy individuals: a phase I, randomized crossover trial.胃肠道促动力剂红霉素对健康个体中普瑞巴林控释制剂药代动力学的影响:一项I期随机交叉试验。
Clin Drug Investig. 2015 May;35(5):299-305. doi: 10.1007/s40261-015-0281-y.
3
Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects.健康受试者口服普瑞巴林后痛觉模型的群体药代动力学/药效学分析。
CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):573-580. doi: 10.1002/psp4.12318. Epub 2018 Aug 13.
4
Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures.健康受试者和慢性疼痛或部分发作患者中普瑞巴林的群体药代动力学。
Epilepsia. 2011 Feb;52(2):248-57. doi: 10.1111/j.1528-1167.2010.02933.x. Epub 2011 Jan 26.
5
Clinical pharmacokinetics of pregabalin in healthy volunteers.健康志愿者中普瑞巴林的临床药代动力学。
J Clin Pharmacol. 2010 Aug;50(8):941-50. doi: 10.1177/0091270009352087. Epub 2010 Feb 10.
6
Pregabalin Population Pharmacokinetic and Exposure-Response Analyses for Focal Onset Seizures in Children (4-16 years) and Adults, to Support Dose Recommendations in Children.普瑞巴林用于儿童(4-16 岁)和成人局灶性发作癫痫的群体药代动力学和暴露-反应分析,支持儿童剂量推荐。
Clin Pharmacol Ther. 2021 Jul;110(1):132-140. doi: 10.1002/cpt.2132. Epub 2021 Jan 3.
7
Pharmacokinetic and pharmacodynamic studies of pregabalin suppositories based on pharmacological research.基于药理学研究的普瑞巴林栓剂的药代动力学和药效学研究。
J Pharm Pharmacol. 2019 May;71(5):746-752. doi: 10.1111/jphp.13051. Epub 2018 Dec 4.
8
Pharmacokinetics of single-dose oral pregabalin administration in normal dogs.单剂量口服普瑞巴林在正常犬体内的药代动力学。
Vet Anaesth Analg. 2009 Nov;36(6):574-80. doi: 10.1111/j.1467-2995.2009.00486.x.
9
Saliva versus Plasma Therapeutic Drug Monitoring of Pregabalin in Jordanian Patients.约旦患者中普瑞巴林的唾液与血浆治疗药物监测
Drug Res (Stuttg). 2018 Oct;68(10):596-600. doi: 10.1055/a-0600-2113. Epub 2018 Apr 23.
10
The absorption profile of pregabalin in chronic pancreatitis.普瑞巴林在慢性胰腺炎中的吸收特征。
Basic Clin Pharmacol Toxicol. 2012 Dec;111(6):385-90. doi: 10.1111/j.1742-7843.2012.00914.x. Epub 2012 Jul 11.

引用本文的文献

1
Pregabalin in the Management of Painful Diabetic Neuropathy: A Narrative Review.普瑞巴林用于治疗疼痛性糖尿病神经病变:一项叙述性综述
Diabetes Ther. 2019 Feb;10(1):35-56. doi: 10.1007/s13300-018-0550-x. Epub 2018 Dec 18.
2
Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects.健康受试者口服普瑞巴林后痛觉模型的群体药代动力学/药效学分析。
CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):573-580. doi: 10.1002/psp4.12318. Epub 2018 Aug 13.

本文引用的文献

1
The absorption profile of pregabalin in chronic pancreatitis.普瑞巴林在慢性胰腺炎中的吸收特征。
Basic Clin Pharmacol Toxicol. 2012 Dec;111(6):385-90. doi: 10.1111/j.1742-7843.2012.00914.x. Epub 2012 Jul 11.
2
Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model).实现剂量叠加,为数学吸收模型(转运室模型)引入多个剂量。
J Pharmacokinet Pharmacodyn. 2012 Jun;39(3):251-62. doi: 10.1007/s10928-012-9247-3. Epub 2012 May 4.
3
Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy.
健康受试者和带状疱疹后神经痛或糖尿病周围神经病变患者中普瑞巴林的群体药代动力学。
Br J Clin Pharmacol. 2011 Jul;72(1):63-76. doi: 10.1111/j.1365-2125.2011.03932.x.
4
Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures.健康受试者和慢性疼痛或部分发作患者中普瑞巴林的群体药代动力学。
Epilepsia. 2011 Feb;52(2):248-57. doi: 10.1111/j.1528-1167.2010.02933.x. Epub 2011 Jan 26.
5
Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies.评估普瑞巴林治疗老年神经病理性疼痛患者的安全性和疗效:11 项临床研究的汇总分析结果。
BMC Fam Pract. 2010 Nov 5;11:85. doi: 10.1186/1471-2296-11-85.
6
Can a single dose of 300 mg of pregabalin reach acute antihyperalgesic levels in the central nervous system?普瑞巴林 300 毫克单剂量能否达到中枢神经系统的急性抗痛觉过敏水平?
Reg Anesth Pain Med. 2010 Nov-Dec;35(6):535-8. doi: 10.1097/AAP.0b013e3181fa6b7a.
7
Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain.在神经病理性疼痛大鼠模型中,对普瑞巴林和西地那非的静态痛觉过敏反应进行药代动力学-药效学分析。
J Pharmacol Exp Ther. 2010 Aug;334(2):599-608. doi: 10.1124/jpet.110.166074. Epub 2010 May 5.
8
Clinical pharmacokinetics of pregabalin in healthy volunteers.健康志愿者中普瑞巴林的临床药代动力学。
J Clin Pharmacol. 2010 Aug;50(8):941-50. doi: 10.1177/0091270009352087. Epub 2010 Feb 10.
9
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.利福平在肺结核患者中的群体药代动力学,包括一个描述可变吸收的半机制模型。
Antimicrob Agents Chemother. 2008 Jun;52(6):2138-48. doi: 10.1128/AAC.00461-07. Epub 2008 Apr 7.
10
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.用于在药代动力学研究中描述药物吸收的转运室模型的实施。
J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):711-26. doi: 10.1007/s10928-007-9066-0. Epub 2007 Jul 26.